Please assess the completion status of the following clinical trial:

Trial Title: A Multi-center 12-week Study of HMS5552 in T2DM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Male \& female, 40\~75 years old~2. T2DM patients，anti-hyperglycemic drug-naïve and on diet \& exercise for at least 3 months, or with glucose controlled by Metformin or α-glucosidase inhibitor alone~3. HbA1c 7.5\~10.5% at screening and pre-randomization~4. Fasting plasma glucose (FPG)7.0\~11.1 millimole/liter (mmol/L, local lab) at screening, and 7.0\~13.3 millimole/liter (mmol/L, central lab) at pre-randomization~5. BMI: 19\~30kg/m\^2 \& TG\<5.5mmol/L~Exclusion Criteria:~1. T1D，secondary DM, pre-DM~2. kidney diseases or eGFR MDRD\<60ml/min/1.73m\^2~3. unstable CVDs~4. liver diseases~5. mental or CNS diseases

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- HMS5552 dose 1 (Type: EXPERIMENTAL): 75mgQD oral administration
- HMS5552 dose 2 (Type: EXPERIMENTAL): 100mgQD oral administration
- HMS5552 dose 3 (Type: EXPERIMENTAL): 50mgBID oral administration
- HMS5552 dose 4 (Type: EXPERIMENTAL): 75mgBID oral administration
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, BID/QD oral administration

Based on this trial design, predict the completion outcome and termination type (if applicable).